Despite finally winning a hard-fought FDA approval for its chronic kidney disease (CKD) anemia drug Vafseo last year, Akebia ...

We are committed to increasing the scientific understanding of the cardiovascular risk that persists beyond traditional therapies and advancing the treatment of that risk for patients worldwide.

brings in place time-bound dispute resolution mechanism and transparency in determining tariffs. But will at the same time lay down stringent provisions for prevention and containment of pollution ...

Another life was lost on Monday at the Chest Surgery Unit of Mayo Hospital due to an alleged adverse drug reaction, sending shockwaves through the ward. Fourteen other patients remain in critical ...

An analysis of high school soccer players suggests that incorporating a lower extremity injury prevention program results in ...

CARVYKTI® net trade sales of approximately $334 million and $963 million for the fourth quarter and full year 2024, respectivelyOver 5,000 patients treated to dateInitiated commercial production of CA ...

Poor treatment adherence remains a major obstacle in national tuberculosis programmes globally. Digital adherence technologies offer novel opportunities to monitor and address poor adherence. Research ...

Achieved record quarterly sales of $11.4 million in Q4 2024, an increase of 27% compared with Q4 2023 Full year 2024 revenue increased nearly 30% YoY to $41 million Exceeded full year 2024 operating ...

Dr Adam Friedman recounts how AAD 2025 highlighted advancements in chronic spontaneous urticaria management, with discussion on new therapies and the role of diet.

In a Q&A, NIH addiction chief Nora Volkow speaks about RFK Jr.'s policy shake-ups, 12-step recovery limits, and why overdose ...